



ISSN: 2348-6295

Journal of Pharma Creations (JPC)

JPC | Vol.11 | Issue 2 | Apr - Jun -2024

www.pharmacreations.com

DOI : <https://doi.org/10.61096/jpc.v11.iss2.2024.74-79>

Review



Happi Gummies Melatonin; A Sleep Care Gummy

GovindShukla¹, Dr. Chandramauli², Dr. Balaswamy N.G³, Dr. G. Lohitha⁴,
Dr. Rajkumar⁵, Dr. C. J. Sampath Kumar⁶

Pugos Nutrition Research Centre Hyderabad, A unit of PUGOS Products Pvt. Ltd. 42, 2nd Floor, Leelavathi Mansion, 6th Cross, Margosa Main Road Malleshwaram Bangalore-56003, India.

* Author for Correspondence: GovindShukla

Email: lactonovaresearch44@gmail.com

	Abstract
Published on: 08 May 2024	<p>Gummy bears (German: <i>Gummibär</i>) are small, fruit gum candies, similar to a jelly baby. The candy is roughly 2 cm (0.8 in) long and shaped in the form of a bear. Melatonin is a hormone secreted by the enigmatic pineal gland in response to darkness, hence the name <i>hormone of darkness</i>. It has generated a great deal of interest as a therapeutic modality for various diseases particularly sleep disorders. This pleiotropic molecule has anti-inflammatory, antioxidant and anticoagulopathic properties in addition to its endothelial protective effects. In this article we discuss melatonin secretion and mechanisms of action as well as therapeutic rationale. We also highlight the potential utility of melatonin in the deadly modern-day Ebola epidemic.</p>
Published by: DrSriram Publications	
2024 All rights reserved.	
	<p>Keywords: Ebola, Human, Jetlag, Melatonin, Pineal, Sleep</p>
<p>Creative Commons Attribution 4.0 International License.</p>	

INTRODUCTION

Shaped like a pinecone, the enigmatic pineal gland that is deeply seated in the brain has ignited the imagination of scholars and philosophers as well as spirituals from various cultures throughout generations and has been dubbed the “third eye” and “the seat of the soul” by René Descartes and was conceptualized as a ‘tranquilizing organ [1,2]. Interestingly, investigators suggested the pineal gland, and its hormone product melatonin, to be possibly associated with longevity [3,4] and that pineal gland dysfunction and eventual failure is what initiates the aging process [5]. The first evidence that the pineal gland secretes a biologically active compound, now known as melatonin, was demonstrated by the ability of the pineal tissue extracts from bovine sources to alter melanin pigmentation in frogs, causing melanin aggregation, giving rise to the name melatonin [6,7]. These findings have led to the attempts of using melatonin as a treatment for vitiligo, which has proven to be largely ineffective. However, this research had led to the incidental discovery of the sleep-promoting effects of melatonin [8,9].

Melatonin Synthesis, Storage and Release

Melatonin is the only known hormone synthesized by the pineal gland and is released in response to darkness hence the name, “hormone of darkness” [10]. Melatonin provides a circadian and seasonal signal to the organisms in vertebrates. Melatonin is produced from serotonin (made from tryptophan), through a cascade of enzymatic reactions (Figure 1). The last two steps in the pathway include the conversion of serotonin to N-acetylserotonin (NAS) catalyzed by the enzyme arylalkylamine N acetyltransferase (AANAT) followed by the conversion of N-acetylserotonin to melatonin catalyzed by the enzyme hydroxyl-indole-O-methyltransferase (HIOMT) [8].




Fig 1: Enzymatic reactions

Biosynthesis of serotonin and melatonin.

The pineal gland receives input from postganglionic fibers, leading to the release of noradrenaline and increased production of cyclic AMP, thus activating the enzyme AANAT, mentioned above, which is critical to the production of melatonin. The neurohormone melatonin is not stored in the pineal gland but rather is released into the bloodstream and can penetrate all body tissues [11]. It is important to note that “darkness” stimulates the pineal gland to secrete melatonin whereas exposure to light inhibits this mechanism [12].

Interestingly, the pineal gland, while embryologically part of the brain, is located outside the blood brain barrier and loses its connections with the central nervous system, having sympathetic innervation as its main source [7]. This perhaps accounts for the ability of the pineal gland to have a large uptake of tryptophan leading to a high melatonin production and secretion in response to darkness. This process also offers relative protection from premature enzymatic degradation which leads to a 10-20 fold increase in plasma melatonin levels that easily diffuses through cell membranes and crosses the blood brain barrier (BBB) [7,13].

Mechanisms of Action of Melatonin and Therapeutic Rationale

With the increasing prevalence of sleep disorders associated with the epidemic of obesity, there has been a great deal of renewed interest in melatonin, its mechanism of action and its therapeutic effects. Sleep disorders, regardless of the etiology, are becoming frequently encountered by physicians and other health care providers. According to data from the Center for Disease Control (CDC), up to about 70 million Americans suffer from chronic sleep problems [14], which are generally associated with obesity, diabetes, hypertension and increased cardiovascular risk. While increasingly common in the general population coupled with obesity, sleep disorders are disproportionately severe and associated with increased cardiovascular risk among minority populations [15,16]. Sleep disorders are also commonly associated with other comorbidities as well including dementias, chronic pain, mental illness and gastrointestinal disorders [17]. Unfortunately, irrespective of the high prevalence

and the serious health consequences, sleep disorders often go undiagnosed and largely undertreated [18]. It is therefore critical to properly diagnose and treat certain types of circadian rhythm sleep disorders such as advanced sleep phase syndrome (ASPS), shift-work sleep disorder, and jetlag [19,20].

Although melatonin has effects on various cells in the human body [21], its sleep-promoting actions are mostly caused by its feedback to the suprachiasmatic nucleus (SCN; the master clock), specifically on the melatonin receptors (MT1 and MT2) [22]. By working on the SCN, melatonin helps to synchronize the circadian rhythm by affecting both the phase and amplitude of the rhythm [23,24]. It is proposed that neuronal firing is suppressed through MT1 receptors whereas MT2 receptors are responsible for phase shifting [23]. Thus, therapy with melatonin and related compounds has been often investigated and is a topic of interest for scholarly research.

Melatonin is sometimes prescribed to patients with sleep disturbances and has been shown to be effective in helping to treat certain sleep disorders such as jet lag [19,20] and insomnia in the elderly [25]. In a meta-analysis study performed by Brzezinski, et al. in 2005 that included 15 studies of patients with only insomnia, melatonin treatment was shown to significantly reduce sleep onset latency, increase sleep efficiency and increase sleep duration [26]. Additionally, in a recent meta-analysis performed by Ferracioli-Oda, et al., (2013), melatonin was again found to significantly reduce sleep onset latency and increase total sleep time, when compared to placebo [27]. There were also clinical trials involving elderly insomniacs and patients with Alzheimer's disease who were suffering from sleep disturbances and showed improvement with exogenous melatonin [8].

Administration and Safety Profile of Melatonin

With regards to the actual administration of melatonin, it has been shown that the timing of melatonin administration, and not so much the actual dosage, is crucial in producing the best results; this is secondary to the normal physiologic function of the circadian rhythm [11]. For example, it was found that when melatonin was administered at bedtime as a “sleeping pill”, it was not effective unless high doses were used [11,28]; however, when small doses of melatonin were administered to patients about 2 to 4 hours before bedtime, it was shown to be effective in decreasing sleep latency [29].

The side effect profile of melatonin therapy is quite reassuring and is largely superior to other sleep-inducing agents. For example, melatonin therapy does not cause withdrawal or dependence symptoms unlike benzodiazepines (BZDs) and z-drugs such as Zolpidem [23]. Some of potential harmful effects of exogenous melatonin therapy include immunomodulatory effects which confers the risk of worsening certain rheumatologic condition such as rheumatoid arthritis [30]. It might also result in amenorrhea when used in large doses, which is likely due to suppression of gonadotropin-releasing hormone (GnRH) [31]. However, this effect is readily reversible with cessation of the medication.

Role of Melatonin-Related Formulations

Starting in 2005, several melatonin-related compounds were introduced including Ramelteon that is an agonist of MT1 and MT2 receptors with a longer half-life compared to melatonin [23]. This medication was approved in the USA by the FDA in 2005 as a treatment for insomnia [32]. It has been shown to have a much greater affinity to the MT1 and MT2 receptors when compared to melatonin itself [33]. A randomized controlled study performed by Erman, et al. found that Ramelteon is effective in decreasing the latency period to persistent sleep in various dosages [34]. Like melatonin therapy, Ramelteon was not shown to be associated with hangover effects or withdrawal symptoms [35].

Another interesting agent that has been recently FDA approved is Agomelatine. Besides its actions as an agonist on MT1 and MT2 receptors, this medication has the additional advantage of being an antagonist on the 5-HT_{2c} serotonin receptor [36]. Aside from its potent antidepressive effects, this drug promotes sleep, an advantage that is lacking in most antidepressive agents. In fact, many antidepressants that are currently available can actually worsen sleep, instead of benefit it [23,37].

One intriguing question that has arisen over the years is how blindness affects the circadian rhythm since input from the retina is compromised. Although a study performed by Czeisler, et al. in 1995 showed that some blind individuals, with no conscious perception of light, were still able to inhibit melatonin secretion when exposed to light [38], disruption of the sleep-wake cycle in blind individuals remains a target for investigation. Fortunately, based on the results of two published trials, a new agent Tasimelteon, was approved in 2014 for the treatment of a condition known as “non-24 hour” sleep disorder in blind patients [39]. This drug, another MT1 and MT2 receptor agonist, was shown to be superior when compared to placebo in facilitating entrainment of the circadian rhythm as well as the increasing night-time sleep in studied “non 24-hour” blind patients [40].

Melatonin as a Possible Therapeutic Option for Ebola virus

Melatonin, a versatile and pluripotent molecule, has been shown to have several beneficial effects above and beyond its highly celebrated property of sleep promotion (Figure 2).




Fig 2: Several beneficial effects above and beyond its highly celebrated property of sleep promotion

The pleiotropy of melatonin

While melatonin has been shown to exhibit protective effects against certain neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease [3,41,42] and sundowning syndrome [43,44], perhaps the most exciting of these pleiotropic effects include anti-inflammatory, antioxidant, anticoagulopathic as well as endothelial-protective properties [45-48]. This has led to an exciting hypothesis by Dun-Xian Tan, et al. from the University of Texas in a recently published article highlighting these various beneficial effects of melatonin and proposing it as potential treatment for Ebola [49], a highly dreaded modern-day epidemic that has claimed over 4,500 lives thus far without a glimpse of hope for an effective therapeutic strategy in sight.

The pathogenetic mechanisms of Ebola virus infection, as eloquently outlined by Tan, et al., (2014) which include inflammation, coagulopathy, as well as endothelial disruption. These mechanisms are quite similar to the pathogenetic processes observed in septic shock albeit due to different offending agents, viral vs. bacterial [49]. While melatonin possesses pro- and anti-inflammatory properties, these contradictory characteristics reflect more anti-inflammatory benefits in advanced stages of inflammation [46]. Melatonin also has a favorable effect on coagulopathy, as demonstrated in a placebo-controlled study where a single dose of oral melatonin lowered plasma levels of procoagulant factors 60 minutes post-administration [48]. Accumulating evidence also indicates that melatonin ameliorates vascular endothelial dysfunction in several conditions such as hypertension, atherosclerosis, diabetes, reperfusion injury and nicotine-induced vasculopathy [47]. In a study involving high fat-fed rabbits, melatonin was shown to improve vascular endothelial function and inflammation and to inhibit the progression of atherosclerosis [45]. Furthermore, evidence exists indicating possible direct anti-viral effects of melatonin [49, 50]. This has been suggested in a single-blinded, randomized study comparing acyclovir vs. melatonin added to a mixture of magnesium, phosphate, and fatty acids extracted from an *Aspergillus* species with known anti-viral properties in the treatment of patients with Herpes. The melatonin group was superior to the Acyclovir group in the regression of Herpes symptoms after 7 days of administration [51]. Collectively, this wide range of melatonin effects makes this pluripotent molecule an attractive therapeutic choice for Ebola virus, addressing the major pathogenetic pathways of this devastating illness, as proposed by Tan, et al. [49]. Although we believe that melatonin is unlikely to eradicate the virus or curb its proliferation, the authors of this commentary are in support of this approach given the current lack of effective therapeutic alternatives as well as the highly favorable safety profile of melatonin.

CONCLUSION

Over the decades, melatonin, an ancient, ubiquitous, and a pleiotropic molecule, which was frequently used as a popular supplement by the general public and had many media hypes and frenzy as well as cult status with unjustified therapeutic claims often resulted in tight scrutiny [52]. For example, melatonin was known as the Dracula hormone, Princess Diana drug, the sleep hormone, chemical expression of darkness, the hormone of darkness, nature's sleeping pill, universal panacea, miracle hormone, and the elixir of life. Nevertheless, substantial research over the years in many facets of melatonin has demystified the potentials roles of melatonin, thereby exceeding the expectations in terms of protecting human health.

REFERENCES

1. Booth FM. The human pineal gland: a review of the “third eye” and the effect of light. *Aust N Z J Ophthalmol.* 1987;15:329–336. [PubMed] [Google Scholar]
2. Romijn HJ. The pineal, a tranquillizing organ? *Life Sci.* 1978;23:2257–2273. [PubMed] [Google Scholar]
3. Srinivasan V, Cardinali DP, Srinivasan US, Kaur C, Brown GM, et al. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. *Ther Adv Neurol Disord.* 2011;4:297–317. [PMC free article] [PubMed] [Google Scholar]
4. Oaknin-Bendahan S, Anis Y, Nir I, Zisapel N. Effects of long-term administration of melatonin and a putative antagonist on the ageing rat. *Neuroreport.* 1995;6:785–788. [PubMed] [Google Scholar]
5. Rozenzweig R, Grad BR, Ochoa J. The role of melatonin and serotonin in aging. *Med Hypotheses.* 1987;23:337–352. [PubMed] [Google Scholar]
6. McCord C, Allen FP. Evidences associating pineal gland function of alterations in pigmentation. *SO J Exptl Zool.* 1917;23:207. [Google Scholar]
7. Wurtman R. *Physiology and Clinical Use of Melatonin* [Google Scholar]
8. Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. *Exp Gerontol.* 2005;40:911–925. [PubMed] [Google Scholar]
9. Lerner AB, Case JD. Melatonin. *Fed.Proc.* 1960;19:590–592. [Google Scholar]
10. Srinivasan V, Spence WD, Pandi-Perumal SR, Zakharia R, Bhatnagar KP, et al. Melatonin and human reproduction: shedding light on the darkness hormone. *Gynecol Endocrinol.* 2009;25:779–785. [PubMed] [Google Scholar]
11. Luboshizsky R, Lavie P. Sleep-inducing effects of exogenous melatonin administration. *Sleep Med Rev.* 1998;2:191–202. [PubMed] [Google Scholar]
12. Hardeland R. Chronobiology of Melatonin beyond the Feedback to the Suprachiasmatic Nucleus-Consequences to Melatonin Dysfunction. *Int J Mol Sci.* 2013;14:5817–5841. [PMC free article] [PubMed] [Google Scholar]
13. Wurtman RJ, Axelrod J, Potter LT. The Uptake of H3-Melatonin in Endocrine and Nervous Tissues and the Effects of Constant Light Exposure. *J pharmacol exp ther.* 1964;143:314–318. [PubMed] [Google Scholar]
14. Colten HR, Altevogt BM, editors. *Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem.* Washington (DC): 2006. [PubMed] [Google Scholar]
15. Donat M, Brown C, Williams N, Pandey A, Racine C, et al. Linking sleep duration and obesity among black and white US adults. *Clin Pract (Lond)* 2013;10:5. [PMC free article] [PubMed] [Google Scholar]
16. Zizi F, Pandey A, Murray-Bachmann R, Vincent M, McFarlane S, et al. Race/ethnicity, sleep duration, and diabetes mellitus: analysis of the National Health Interview Survey. *Am J Med.* 2012;125:162–167. [PMC free article] [PubMed] [Google Scholar]
17. Skaer TL, Sclar DA. Economic implications of sleep disorders. *Pharmacoeconomics.* 2010;28:1015–1023. [PubMed] [Google Scholar]
18. Hossain JL, Shapiro CM. The prevalence, cost implications, and management of sleep disorders: an overview. *Sleep Breath.* 2002;6:85–102. [PubMed] [Google Scholar]
19. Brown GM, Pandi-Perumal SR, Trakht I, Cardinali DP. Melatonin and its relevance to jet lag. *Travel Med Infect Dis.* 2009;7:69–81. [PubMed] [Google Scholar]
20. Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. *Cochrane Database Syst Rev.* 2001:CD001520. [PubMed] [Google Scholar]
21. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. *Endocrine.* 2005;27:101–110. [PubMed] [Google Scholar]
22. Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Poeggeler B, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. *Int J Neurosci.* 2009;119:821–846. [PubMed] [Google Scholar]
23. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, et al. Melatonergic drugs in clinical practice. *Arzneimittelforschung.* 2008;58:1–10. [PubMed] [Google Scholar]
24. Pévet P, Bothorel B, Slotten H, Saboureaux M. The chronobiotic properties of melatonin. *Cell Tissue Res.* 2002;309:183–191. [PubMed] [Google Scholar]
25. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, et al. Melatonin replacement therapy of elderly insomniacs. *Sleep.* 1995;18:598–603. [PubMed] [Google Scholar]
26. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, et al. Effects of exogenous melatonin on sleep: a meta-analysis. *Sleep Med Rev.* 2005;9:41–50. [PubMed] [Google Scholar]
27. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. *PLoS One.* 2013;8:e63773. [PMC free article] [PubMed] [Google Scholar]

28. Cramer H, Rudolph J, Consbruch U, Kendel K. On the effects of melatonin on sleep and behavior in man. *Adv Biochem Psychopharmacol.* 1974;11:187–191. [PubMed] [Google Scholar]
29. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovskaya VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. *Sleep.* 1996;19:423–431. [PubMed] [Google Scholar]
30. Maestroni GJ, Cardinali DP, Esquifino AI, Pandi-Perumal SR. Does melatonin play a disease-promoting role in rheumatoid arthritis? *J Neuroimmunol.* 2005;158:106–111. [PubMed] [Google Scholar]
31. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, et al. Melatonin: Nature's most versatile biological signal? *FEBS J.* 2006;273:2813–2838. [PubMed] [Google Scholar]
32. Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. *Expert Rev Neurother.* 2006;6:957–964. [PubMed] [Google Scholar]
33. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. *Neuropharmacology.* 2005;48:301–310. [PubMed] [Google Scholar]
34. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. *Sleep Med.* 2006;7:17–24. [PubMed] [Google Scholar]
35. Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. *Adv Ther.* 2009;26:613–626. [PubMed] [Google Scholar]
36. Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti MJ. Could agomelatine be the ideal antidepressant? *Expert Rev Neurother.* 2006;6:1595–1608. [PubMed] [Google Scholar]
37. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. *Int Clin Psychopharmacol 21 Suppl.* 2006;1:S25–29. [PubMed] [Google Scholar]
38. Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, et al. Suppression of melatonin secretion in some blind patients by exposure to bright light. *N Engl J Med.* 1995;332:6–11. [PubMed] [Google Scholar]
39. Johnsa J, Neville MW. Tasimelteon: A Melatonin Receptor Agonist for Non-24 Sleep-Wake Disorder. *Ann Pharmacother.* 2014 [PubMed] [Google Scholar]
40. Lockley SMD, Torres R, Lavedan C, Licamele LM. Polymeropoulos Tasimelteon treatment entrains the circadian clock and demonstrates significant benefit on sleep and wake parameters in totally blind individuals with non-24 hour circadian rhythms. *Sleep Medicine.* 2013;14:178. [Google Scholar]
41. Pandi-Perumal SR, BaHamam AS, Brown GM, Spence DW, Bharti VK, et al. Melatonin antioxidative defense: therapeutic implications for aging and neurodegenerative processes. *Neurotox Res.* 2013;23:267–300. [PubMed] [Google Scholar]
42. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. *Behav Brain Funct.* 2006;2:15. [PMC free article] [PubMed] [Google Scholar]
43. Bedrosian TA, Nelson RJ. Sundowning syndrome in aging and dementia: research in mouse models. *Exp Neurol.* 2013;243:67–73. [PubMed] [Google Scholar]
44. de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. *Int J Geriatr Psychiatry.* 2010;25:1201–1208. [PubMed] [Google Scholar]
45. Hu ZP, Fang XL, Fang N, Wang XB, Qian HY, et al. Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF- κ B system in high-fat-fed rabbits. *J Pineal Res.* 2013;55:388–398. [PubMed] [Google Scholar]
46. Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. *Biochem Pharmacol.* 2010;80:1844–1852. [PubMed] [Google Scholar]
47. Rodella LF, Favero G, Foglio E, Rossini C, Castrezzati S, et al. Vascular endothelial cells and dysfunctions: role of melatonin. *Front Biosci (Elite Ed)* 2013;5:119–129. [PubMed] [Google Scholar]
48. Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. *J Pineal Res.* 2008;44:127–133. [PubMed] [Google Scholar]
49. Tan DX, Korkmaz A, Reiter RJ, Manchester LC. Ebola virus disease: potential use of melatonin as a treatment. *J Pineal Res.* 2014;57:381–384. [PubMed] [Google Scholar]
50. Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman”? *Rev Med Virol.* 2012;22:323–338. [PMC free article] [PubMed] [Google Scholar]
51. Nunes Oda S, Pereira Rde S. Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir. *J Pineal Res.* 2008;44:373–378. [PubMed] [Google Scholar]